| 414- | CUR, | Transcriptome Investigation and In Vitro Verification of Curcumin-Induced HO-1 as a Feature of Ferroptosis in Breast Cancer Cells |
| - | in-vitro, | BC, | MCF-7 | - | in-vitro, | BC, | MDA-MB-231 |
| 437- | CUR, | Anti-cancer activity of amorphous curcumin preparation in patient-derived colorectal cancer organoids |
| - | vitro+vivo, | CRC, | TCO1 | - | vitro+vivo, | CRC, | TCO2 |
| 436- | CUR, | Integrated microRNA and gene expression profiling reveals the crucial miRNAs in curcumin anti‐lung cancer cell invasion |
| - | in-vitro, | Lung, | A549 |
| 435- | CUR, | Antitumor activity of curcumin by modulation of apoptosis and autophagy in human lung cancer A549 cells through inhibiting PI3K/Akt/mTOR pathway |
| - | in-vitro, | Lung, | A549 |
| 434- | CUR, | Curcumin induces apoptosis in lung cancer cells by 14-3-3 protein-mediated activation of Bad |
| - | in-vitro, | Lung, | A549 |
| 433- | CUR, | Curcumin Inhibits the Migration and Invasion of Non-Small-Cell Lung Cancer Cells Through Radiation-Induced Suppression of Epithelial-Mesenchymal Transition and Soluble E-Cadherin Expression |
| - | in-vitro, | Lung, | A549 |
| 432- | CUR, | Curcumin-Induced Global Profiling of Transcriptomes in Small Cell Lung Cancer Cells |
| - | in-vitro, | Lung, | H446 |
| 431- | CUR, | Curcumin suppresses the stemness of non-small cell lung cancer cells via promoting the nuclear-cytoplasm translocation of TAZ |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | Lung, | H1299 |
| 430- | CUR, | Curcumin suppresses tumor growth of gemcitabine-resistant non-small cell lung cancer by regulating lncRNA-MEG3 and PTEN signaling |
| - | vitro+vivo, | Lung, | A549 |
| 457- | CUR, | Curcumin regulates proliferation, autophagy, and apoptosis in gastric cancer cells by affecting PI3K and P53 signaling |
| - | in-vitro, | GC, | SGC-7901 | - | in-vitro, | GC, | BGC-823 |
| 438- | CUR, | Curcumin Reduces Colorectal Cancer Cell Proliferation and Migration and Slows In Vivo Growth of Liver Metastases in Rats |
| - | vitro+vivo, | CRC, | CC531 |
| 417- | CUR, | Curcumin inhibits the growth of triple‐negative breast cancer cells by silencing EZH2 and restoring DLC1 expression |
| - | vitro+vivo, | BC, | MCF-7 | - | vitro+vivo, | BC, | MDA-MB-231 | - | vitro+vivo, | BC, | MDA-MB-468 |
| 420- | CUR, | Anti-metastasis activity of curcumin against breast cancer via the inhibition of stem cell-like properties and EMT |
| - | in-vitro, | BC, | MCF-7 | - | in-vitro, | BC, | MDA-MB-231 |
| 422- | CUR, | Curcumin induces re-expression of BRCA1 and suppression of γ synuclein by modulating DNA promoter methylation in breast cancer cell lines |
| - | in-vitro, | BC, | HCC-38 | - | in-vitro, | BC, | T47D |
| 423- | CUR, | Inhibition of TLR4/TRIF/IRF3 Signaling Pathway by Curcumin in Breast Cancer Cells |
| - | in-vitro, | BC, | MCF-7 | - | in-vitro, | BC, | MDA-MB-231 |
| 424- | CUR, | Curcumin inhibits autocrine growth hormone-mediated invasion and metastasis by targeting NF-κB signaling and polyamine metabolism in breast cancer cells |
| - | in-vitro, | BC, | MCF-7 | - | in-vitro, | BC, | MDA-MB-231 |
| 425- | CUR, | Curcumin inhibits proliferation and promotes apoptosis of breast cancer cells |
| - | in-vitro, | BC, | T47D | - | in-vitro, | BC, | MCF-7 | - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | MDA-MB-468 |
| 426- | CUR, | Use of cancer chemopreventive phytochemicals as antineoplastic agents |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | CAL51 |
| 427- | CUR, | Curcumin suppresses the malignancy of non-small cell lung cancer by modulating the circ-PRKCA/miR-384/ITGB1 pathway |
| - | in-vitro, | Lung, | H1299 | - | in-vitro, | Lung, | H460 | - | vitro+vivo, | Lung, | A549 |
| 429- | CUR, | TAp63α Is Involved in Tobacco Smoke-Induced Lung Cancer EMT and the Anti-cancer Activity of Curcumin via miR-19 Transcriptional Suppression |
| - | in-vitro, | Lung, | H1299 | - | in-vitro, | Lung, | A549 |
| 447- | CUR, | OXA, | Curcumin reverses oxaliplatin resistance in human colorectal cancer via regulation of TGF-β/Smad2/3 signaling pathway |
| - | vitro+vivo, | CRC, | HCT116 |
| 456- | CUR, | Curcumin Promoted miR-34a Expression and Suppressed Proliferation of Gastric Cancer Cells |
| - | vitro+vivo, | GC, | SGC-7901 |
| 455- | CUR, | Curcumin Affects Gastric Cancer Cell Migration, Invasion and Cytoskeletal Remodeling Through Gli1-β-Catenin |
| - | in-vitro, | GC, | SGC-7901 |
| 454- | CUR, | Curcumin-Induced DNA Demethylation in Human Gastric Cancer Cells Is Mediated by the DNA-Damage Response Pathway |
| - | in-vitro, | GC, | MGC803 |
| 453- | CUR, | Cellular uptake and apoptotic properties of gemini curcumin in gastric cancer cells |
| - | in-vitro, | GC, | AGS |
| 452- | CUR, | Curcumin downregulates the PI3K-AKT-mTOR pathway and inhibits growth and progression in head and neck cancer cells |
| - | vitro+vivo, | HNSCC, | SCC9 | - | vitro+vivo, | HNSCC, | FaDu | - | vitro+vivo, | HNSCC, | HaCaT |
| 451- | CUR, | The effect of Curcumin on multi-level immune checkpoint blockade and T cell dysfunction in head and neck cancer |
| - | vitro+vivo, | HNSCC, | SCC15 | - | vitro+vivo, | HNSCC, | SNU1076 | - | vitro+vivo, | HNSCC, | SNU1041 |
| 450- | CUR, | Curcumin may be a potential adjuvant treatment drug for colon cancer by targeting CD44 |
| - | in-vitro, | CRC, | HCT116 | - | in-vitro, | CRC, | HCT8 |
| 449- | CUR, | Curcumin Suppresses the Colon Cancer Proliferation by Inhibiting Wnt/β-Catenin Pathways via miR-130a |
| - | vitro+vivo, | CRC, | SW480 |
| 448- | CUR, | Heat shock protein 27 influences the anti-cancer effect of curcumin in colon cancer cells through ROS production and autophagy activation |
| - | in-vitro, | CRC, | HT-29 |
| - | in-vitro, | CRC, | SW480 |
| 445- | CUR, | Curcumin Regulates the Progression of Colorectal Cancer via LncRNA NBR2/AMPK Pathway |
| - | in-vitro, | CRC, | HCT116 | - | in-vitro, | CRC, | HCT8 | - | in-vitro, | CRC, | SW480 | - | in-vitro, | CRC, | SW-620 |
| 444- | CUR, | Cisplatin, | LncRNA KCNQ1OT1 is a key factor in the reversal effect of curcumin on cisplatin resistance in the colorectal cancer cells |
| - | vitro+vivo, | CRC, | HCT8 |
| 443- | CUR, | Reduced Caudal Type Homeobox 2 (CDX2) Promoter Methylation Is Associated with Curcumin’s Suppressive Effects on Epithelial-Mesenchymal Transition in Colorectal Cancer Cells |
| - | in-vitro, | CRC, | SW480 |
| 442- | CUR, | 5-FU, | Curcumin may reverse 5-fluorouracil resistance on colonic cancer cells by regulating TET1-NKD-Wnt signal pathway to inhibit the EMT progress |
| - | in-vitro, | CRC, | HCT116 |
| 441- | CUR, | Curcumin Regulates ERCC1 Expression and Enhances Oxaliplatin Sensitivity in Resistant Colorectal Cancer Cells through Its Effects on miR-409-3p |
| - | in-vitro, | CRC, | HCT116 |
| 440- | CUR, | Curcumin Reverses NNMT-Induced 5-Fluorouracil Resistance via Increasing ROS and Cell Cycle Arrest in Colorectal Cancer Cells |
| - | vitro+vivo, | CRC, | SW480 | - | vitro+vivo, | CRC, | HT-29 |
| 439- | CUR, | Curcumin suppresses LGR5(+) colorectal cancer stem cells by inducing autophagy and via repressing TFAP2A-mediated ECM pathway |
| - | in-vitro, | CRC, | LGR5 |
| 1108- | CUR, | Curcumin: a potent agent to reverse epithelial-to-mesenchymal transition |
| - | Review, | NA, | NA |
| 1006- | CUR, | The effect of Curcuma longa extract and its active component (curcumin) on gene expression profiles of lipid metabolism pathway in liver cancer cell line (HepG2) |
| - | in-vitro, | Liver, | HepG2 |
| 1034- | CUR, | immuno, | Enhanced anti‐tumor effects of the PD‐1 blockade combined with a highly absorptive form of curcumin targeting STAT3 |
| - | in-vivo, | NA, | NA |
| 170- | CUR, | Curcumin sensitizes TRAIL-resistant xenografts: molecular mechanisms of apoptosis, metastasis and angiogenesis |
| - | vitro+vivo, | Pca, | PC3 |
| 181- | CUR, | The effects of curcumin on the invasiveness of prostate cancer in vitro and in vivo |
| - | vitro+vivo, | Pca, | DU145 |
| 182- | CUR, | RES, | GI, | Chemopreventive anti-inflammatory activities of curcumin and other phytochemicals mediated by MAP kinase phosphatase-5 in prostate cells |
| - | in-vitro, | Pca, | DU145 | - | in-vitro, | Pca, | PC3 | - | in-vitro, | Pca, | LNCaP | - | in-vitro, | Pca, | LAPC-4 |
| 183- | CUR, | Curcumin down-regulates AR gene expression and activation in prostate cancer cell lines |
| - | in-vitro, | Pca, | LNCaP | - | in-vitro, | Pca, | PC3 |
| 169- | CUR, | Curcumin inhibits the expression of vascular endothelial growth factor and androgen-independent prostate cancer cell line PC-3 in vitro |
| - | in-vitro, | Pca, | PC3 |
| 168- | CUR, | Curcumin inhibits Akt/mammalian target of rapamycin signaling through protein phosphatase-dependent mechanism |
| - | in-vitro, | Pca, | PC3 |
| 2312- | CUR, | Dual Role of Reactive Oxygen Species and their Application in Cancer Therapy |
| - | Review, | Var, | NA |
| 2304- | CUR, | Curcumin decreases Warburg effect in cancer cells by down-regulating pyruvate kinase M2 via mTOR-HIF1α inhibition |
| - | in-vitro, | Lung, | H1299 | - | in-vitro, | BC, | MCF-7 | - | in-vitro, | Cerv, | HeLa | - | in-vitro, | Pca, | PC3 | - | in-vitro, | Nor, | HEK293 |
| 2305- | CUR, | Mitochondrial targeting nano-curcumin for attenuation on PKM2 and FASN |
| - | in-vitro, | BC, | MCF-7 |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:% State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid